The Obesity ETF SLIM
Set alert
33.25 USD 0.00 0.00%
As of Mar 12, 3:59 PM ET
33.00 Day range 36.62
33.00 52-week range 43.40
- Open
- 35.36
- Prev close
- 33.25
- Mkt cap
- 11.34M
- Vol
- 6.31K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 33.00
- High
- 36.62
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 33.17
- 200-d avg
- 33.17
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 33.17
- 200-day average
- 33.17
About The Obesity ETF
The investment seeks investment results that correspond generally to the performance, before fees and expenses, of an index which is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including biotechnology, pharmaceutical, health care and medical device companies whose business is focused on obesity and obesity related disease and companies focused on weight loss programs, weight loss supplements, or plus sized apparel. The fund invests at least 80% of its net assets in the stocks that comprise the Solactive Obesity Index. It is non-diversified.
News
- Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3
- Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company
- Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
- Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
- Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
- Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
- Can Viking Therapeutics Carve Out a Place in the Obesity Market?
- Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
- Viking Therapeutics Starts Phase III Development of Obesity Pill
Your note
Sign in to keep a note on SLIM — it syncs with the Stock Master app.